Abstract:Introduction: Current treatment guidelines for adolescents with gender dysphoria recommend therapy with gonadotropin-releasing hormone agonists (GnRHa) and testosterone in transgender males. However, most evidence on the safety and efficacy of testosterone is based on studies in adults. Aim: This study aimed to investigate the efficacy and safety of testosterone treatment in transgender adolescents. Methods: The study included 62 adolescents diagnosed with gender dysphoria who had started GnRHa treatment and had subsequently received testosterone treatment for more than 6 months. Main outcome measure: Virilization, anthropometry, laboratory parameters, and bone mineral density (BMD) were analyzed. Results: Adolescents were treated with testosterone for a median duration of 12 months. Voice deepening began within 3 months in 85% of adolescents. Increased hair growth was first reported on the extremities, followed by an increase of facial hair. Acne was most prevalent between 6 and 12 months of testosterone therapy. Most adolescents had already completed linear growth; body mass index and systolic blood pressure increased but diastolic blood pressure did not change. High-density lipoprotein (HDL) cholesterol and sex hormone binding globulin significantly decreased, but hematocrit, hemoglobin, prolactin, androstenedione, and dehydroepiandrosterone sulfate significantly increased, although not all changes were clinically significant. Other lipids and HbA1c did not change. Vitamin D deficiency was seen in 32-54% throughout treatment. BMD z-scores after 12 to 24 months of testosterone treatment remained below z-scores before the start of GnRHa treatment. Clinical implications: Adolescents need to be counseled about side effects with potential longer term implications such as increased hematocrit and decreased HDL cholesterol and decreased BMD z-scores. They should be advised on diet, including adequate calcium and vitamin D intake; physical exercise; and the use of tobacco and alcohol to avoid additional risk factors for cardiovascular disease and osteoporosis. Strengths & limitations: Strengths are the standardized treatment regimen and extensive set of safety parameters investigated. Limitations are the limited duration of follow-up and lack of a control group so some of the observed changes may be due to normal maturation rather than to treatment. Conclusion: Testosterone effectively induced virilization beginning within 3 months in the majority of adolescents. Acne was a common side effect, but no short-term safety issues were observed. The increased hematocrit, decreased HDL cholesterol, and decreased BMD z-scores are in line with previous studies. Further follow-up studies will need to establish if the observed changes result in adverse outcomes in the long term. Stoffers IE, de Vries MC, Hannema SE. Physical Changes, Laboratory Parameters, and Bone Mineral Density During Testosterone Treatment in Adolescents with Gender Dysphoria. J Sex Med 2019;16:1459-1468.

Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men

Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review

(O-21) Major Adverse Effects Of Anabolic Steroid Use In Transgender Men During Gender-Reaffirming Hormone Therapy: A Systematic Review Of The Literature

Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review

Impact of Gender-Affirming Hormonal Therapy on Cardiovascular Risk Factors in Transgender Health: An Updated Meta-Analysis

Uterine changes in transgender men receiving testosterone therapy

Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans

Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria

Uterine and Ovarian Histopathology After Testosterone for Gender Affirmation: A Systematic Review

Short-Term Changes in Bone Metabolism Among Transgender Men Starting Gender-Affirming Hormone Therapy: A Systematic Review and Meta-analysis

Insulin sensitivity, body composition and bone mineral density after testosterone treatment in transgender youth with and without prior GnRH agonist therapy

Effects of gender‐affirming hormone therapy on lower urinary tract symptoms and sexual function among transgender individuals

Transgender patients and gender-affirming hormone therapy through the mid-life

Effects of gender-affirming hormone therapy on cardiovascular risk factors focusing on glucose metabolism in an Austrian transgender cohort

Association between gender-affirming hormone therapy and measures of glucose metabolism: A longitudinal study

Trans men can achieve adequate muscular development through low‐dose testosterone therapy: A long‐term study on body composition changes

SAT406 Evaluation Of The Emotional And Cognitive Effects Of Hormone Therapy In Transgender Men And Women

Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition

Expected vs. perceived effects of gender-affirming hormone therapy among transmasculine adolescents

Impact of Distinct Anti-Androgen Exposures on the Plasma Metabolome in Feminizing Gender-Affirming Hormone Therapy

Evaluating changes in body composition, bone mass, and metabolic profile in an animal model undergoing transfeminine hormone therapy and physical exercise